Stockreport

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update [Yahoo! Finance]

CureVac N.V. - Ordinary Shares  (CVAC) 
PDF €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into [Read more]